Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK and PD of Seletalisib (UCB5857) in Healthy and Psoriatic Subjects
NCT02303509Phase 1Completed
- Sponsor
- UCB
- Start
- Aug 2013
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of seletalisib in psoriasis (2 arms), sponsored by UCB. Primary endpoint: Incidence of adverse events during the study. Started Aug 2013; status: completed.
02
Drugs
seletalisib
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT02303509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303509.